Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its ...

Witty said he was stepping down for "personal reasons" and has been replaced – effective immediately – by former CEO and ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

The progress made in liver disease research to date presents an opportunity for further advancements in the near future.

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

Just a few months after announcing a plan to separate its drug and cell therapy businesses into two separate companies, ...

Improving Global Access to Life-Changing Therapeutics... Following the successful Boston and London meetings, the ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

That is according to the chief executive of the American Association for the Advancement of Science (AAAS), Sudip Parikh, who ...

Netherlands biotech Azafaros is poised to start phase 3 trials of its lead drug for a trio of rare lysosomal storage ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...